EUVIMEDOpdag EUVIMED
Crossref

Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature

Adrienne Conza iD, Racquel A Bitar iD, Fiona H Lynch iD, Pierre-Olivier Grenier, Elena B Hawryluk iD, Sarah E Servattalab iD

Pediatric Dermatology · 2026-08-18

DOI: 10.1111/pde.70337 ↗

At a glance

Journal article in Pediatric Dermatology, published online on 2026-08-18. Written by Adrienne Conza and 5 co-authors. Institution: UMass Chan Medical School, Worcester, Massachusetts, USA. 24 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background/Objectives This study aims to determine the level of hepatitis B virus (HBV) immunity in patients who had HBV serologic testing prior to starting immunomodulatory medication for dermatologic conditions at a single institution and to review evidence on waning immunity, serologic interpretation, and revaccination.

Methods

We performed a retrospective chart review of pediatric and young adult patients initiated on immunomodulatory therapy for dermatologic conditions who had HBV serologic testing prior to initiation. A focused literature review was conducted on durability of HBV immunity, HBV serologies in the context of immunomodulatory medications, and revaccination recommendations.

Results

In this cohort of 23 children, roughly 40% lacked HBV serologic immunity. Prior studies demonstrated that antibody‐mediated protection is heterogeneous and anti‐HBs titers decline over time. Existing guidelines are largely derived from adult populations. Evidence regarding revaccination strategies is mixed. Notably, absence of detectable anti‐HBs antibodies does not always equate to loss of immune memory or susceptibility to infection.

Conclusions

Anti‐HBs titers are variable and wane over time. Experts agree that patients should receive all recommended vaccinations before starting immunomodulatory therapy and be screened for HBV beforehand, based on adult guidelines. It is uncertain how well these recommendations apply to children, who generally have lower HBV risk and prevalence. Guidance is needed on how to manage pediatric patients without serologic evidence of HBV immunity before beginning biologic treatments.

Subjects

Author keywords

childhepatitis B virusimmunosuppression therapyvaccination

Authors and institutions

  • UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Division of Dermatology, Boston Children's Hospital, Boston, Massachusetts, USA.

ORCID profiles: Adrienne Conza, Racquel A Bitar, Fiona H Lynch, Elena B Hawryluk, Sarah E Servattalab

Cite

APA

Conza, A., Bitar, R. A., Lynch, F. H., Grenier, P. O., Hawryluk, E. B., & Servattalab, S. E. (2026). Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature. Pediatric Dermatology. https://doi.org/10.1111/pde.70337

Vancouver

Conza A, Bitar RA, Lynch FH, Grenier PO, Hawryluk EB, Servattalab SE. Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature. Pediatric Dermatology. 2026. doi:10.1111/pde.70337

BibTeX
@article{Conza2026,
  author = {Conza, Adrienne and Bitar, Racquel A and Lynch, Fiona H and Grenier, Pierre-Olivier and Hawryluk, Elena B and Servattalab, Sarah E},
  title = {Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature},
  journal = {Pediatric Dermatology},
  year = {2026},
  doi = {10.1111/pde.70337}
}
Start for free →